Journal of International Oncology ›› 2023, Vol. 50 ›› Issue (3): 129-137.doi: 10.3760/cma.j.cn371439-20230217-00027
-
Received:2023-02-17Revised:2023-02-27Online:2023-03-08Published:2023-04-12
Cite this article
share this article
"
"
"
| [1] |
Chen SB, Weng HR, Wang G, et al. Prognostic factors and outcome for patients with esophageal squamous cell carcinoma underwent surgical resection alone: evaluation of the seventh edition of the American Joint Committee on Cancer staging system for esophageal squamous cell carcinoma[J]. J Thorac Oncol, 2013, 8(4): 495-501. DOI: 10.1097/JTO.0b013e3182829e2c.
doi: 10.1097/JTO.0b013e3182829e2c |
| [2] |
van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med, 2012, 366(22): 2074-2084. DOI: 10.1056/NEJMoa1112088.
doi: 10.1056/NEJMoa1112088 |
| [3] |
Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase Ⅲ multicenter, randomized, open-label clinical trial[J]. J Clin Oncol, 2018, 36(27): 2796-2803. DOI: 10.1200/JCO.2018.79.1483.
doi: 10.1200/JCO.2018.79.1483 |
| [4] |
中国医师协会放射肿瘤治疗医师分会;中华医学会放射肿瘤治疗学分会; 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南(2022年版)[J]. 国际肿瘤学杂志, 2022, 49(11): 641-657. DOI: 10.3760/cma.j.cn371439-20221011-00129.
doi: 10.3760/cma.j.cn371439-20221011-00129 |
| [5] |
Thomas M, Mortensen HR, Hoffmann L, et al. Proposal for the delineation of neoadjuvant target volumes in oesophageal cancer[J]. Radiother Oncol, 2021, 156: 102-112. DOI: 10.1016/j.radonc.2020.11.032.
doi: 10.1016/j.radonc.2020.11.032 |
| [6] |
Shah MA, Kennedy EB, Catenacci DV, et al. Treatment of locally advanced esophageal carcinoma: ASCO guideline[J]. J Clin Oncol, 2020, 38(23): 2677-2694. DOI: 10.1200/JCO.20.00866.
doi: 10.1200/JCO.20.00866 pmid: 32568633 |
| [7] |
Gao XS, Qiao X, Wu F, et al. Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma[J]. Int J Radiat Oncol Biol Phys, 2007, 67(2): 389-396. DOI: 10.1016/j.ijrobp.2006.09.015.
doi: 10.1016/j.ijrobp.2006.09.015 |
| [8] |
Vazquez-Sequeiros E, Wiersema MJ, Clain JE, et al. Impact of lymph node staging on therapy of esophageal carcinoma[J]. Gastroenterology, 2003, 125(6): 1626-1635. DOI: 10.1053/j.gastro.2003.08.036.
doi: 10.1053/j.gastro.2003.08.036 pmid: 14724814 |
| [9] |
Boivin G, Kalambaden P, Faget J, et al. Cellular composition and contribution of tertiary lymphoid structures to tumor immune infiltration and modulation by radiation therapy[J]. Front Oncol, 2018, 8: 256. DOI: 10.3389/fonc.2018.00256.
doi: 10.3389/fonc.2018.00256 pmid: 30038899 |
| [10] |
So TH, Chan SK, Chan WL, et al. Lymphopenia and radiation dose to circulating lymphocytes with neoadjuvant chemoradiation in esophageal squamous cell carcinoma[J]. Adv Radiat Oncol, 2020, 5(5): 880-888. DOI: 10.1016/j.adro.2020.03.021.
doi: 10.1016/j.adro.2020.03.021 pmid: 33089018 |
| [11] |
Shiraishi Y, Fang P, Xu C, et al. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: a propensity matched analysis of the relative risk of proton versus photon-based radiation therapy[J]. Radiother Oncol, 2018, 128(1): 154-160. DOI: 10.1016/j.radonc.2017.11.028.
doi: S0167-8140(17)32751-2 pmid: 29248170 |
| [12] |
Wang ZW, Zhang W, Dong W, et al. Pathological analysis of extracapsular extension of metastatic lymph node and its potential impact on nodal clinical target volume in the radiotherapy of esophageal squamous cell carcinoma[J]. Neoplasma, 2014, 61(3): 324-330. DOI: 10.4149/neo_2014_042.
doi: 10.4149/neo_2014_042 pmid: 24824935 |
| [13] |
Oppedijk V, van der Gaast A, van Lanschot JJ, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials[J]. J Clin Oncol, 2014, 32(5): 385-391. DOI: 10.1200/JCO.2013.51.2186.
doi: 10.1200/JCO.2013.51.2186 pmid: 24419108 |
| [14] |
Hsu FM, Lee JM, Huang PM, et al. Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma[J]. Int J Radiat Oncol Biol Phys, 2011, 81(4): e593-e599. DOI: 10.1016/j.ijrobp.2011.04.032.
doi: 10.1016/j.ijrobp.2011.04.032 |
| [15] |
Liu T, Ding S, Dang J, et al. Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis[J]. Radiat Oncol, 2019, 14(1): 176. DOI: 10.1186/s13014-019-1388-8.
doi: 10.1186/s13014-019-1388-8 |
| [16] |
Juloori A, Tucker SL, Komaki R, et al. Influence of preoperative radiation field on postoperative leak rates in esophageal cancer patients after trimodality therapy[J]. J Thorac Oncol, 2014, 9(4): 534-540. DOI: 10.1097/JTO.0000000000000100.
doi: 10.1097/JTO.0000000000000100 pmid: 24736077 |
| [17] |
Le Prise E, Etienne PL, Meunier B, et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus[J]. Cancer, 1994, 73(7): 1779-1784. DOI: 10.1002/1097-0142(19940401)73:7<1779::aid-cncr2820730702>3.0.co;2-t.
doi: 10.1002/1097-0142(19940401)73:7<1779::aid-cncr2820730702>3.0.co;2-t pmid: 8137201 |
| [18] | National Comprehensive Cancer Network. NCCN guidelines of esophageal and esophagogastric junction cancers, version 5. 2022[EB/OL]. [2022-06-22]. https://www.nccn.org/. |
| [19] |
Elliott DA, Nabavizadeh N, Kusano AS, et al. Locally advanced esophageal chemoradiation therapy practice patterns: results from a national survey of ASTRO members[J]. Int J Radiat Oncol Biol Phys, 2015, 93(< W>3 Supplement): S219. DOI: 10.1016/j.ijrobp.2015.07.528.
doi: 10.1016/j.ijrobp.2015.07.528 |
| [20] |
Buckstein M, Rhome R, Ru M, et al. Neoadjuvant chemoradiation radiation dose levels for surgically resectable esophageal cancer: predictors of use and outcomes[J]. Dis Esophagus, 2018, 31(5): dox148. DOI: 10.1093/dote/dox148.
doi: 10.1093/dote/dox148 |
| [21] |
Thomas M, Borggreve AS, et al. Radiation dose and pathological response in oesophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery: a multi-institutional analysis[J]. Acta Oncol, 2019, 58(10): 1358-1365. DOI: 10.1080/0284186X.2019.1646432.
doi: 10.1080/0284186X.2019.1646432 pmid: 31432736 |
| [22] |
Yang Y, Xu X, Zhou X, et al. Impact of radiation dose on survival for esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy[J]. Front Oncol, 2020, 10: 1431. DOI: 10.3389/fonc.2020.01431.
doi: 10.3389/fonc.2020.01431 pmid: 32974158 |
| [23] |
Nabavizadeh N, Shukla R, Elliott DA, et al. Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy[J]. Dis Esophagus, 2016, 29(6): 614-620. DOI: 10.1111/dote.12377.
doi: 10.1111/dote.12377 pmid: 26043837 |
| [24] |
Engel S, Awerbuch A, Kwon D, et al. Optimal radiation dosing in concurrent neoadjuvant chemoradiation for resectable esophageal cancer: a meta-analysis[J]. J Gastrointest Oncol, 2019, 10(3): 391-399. DOI: 10.21037/jgo.2019.01.02.
doi: 10.21037/jgo.2019.01.02 pmid: 31183187 |
| [25] |
Qian D, Chen X, Shang X, et al. Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery in patients with locally advanced esophageal squamous cell carcinoma who achieved clinical complete response when induction chemoradiation finished: a phase Ⅱ random[J]. Radiother Oncol, 2022, 174: 1-7. DOI: 10.1016/j.radonc.2022.06.015.
doi: 10.1016/j.radonc.2022.06.015 |
| [26] | Noordman BJ, Spaander MCW, Valkema R, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study[J]. Lancet Oncol, 2018, 19(7): 965-974. DOI: 10.1016/S1470- 2045(18)30201-8. |
| [27] | ClinicalTrials. gov. Comparison of systematic surgery versus surveillance and rescue surgery in operable oesophageal cancer with a complete clinical response to radiochemotherapy (Esostrate)[EB/OL]. [2015-9-16]. https://clinicaltrials.gov/ct2/show/NCT02551458. |
| [28] |
Kato K, Ito Y, Daiko H, et al. A randomized controlled phase Ⅲ trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study[J]. J Clin Oncol, 2022, 40(4_suppl): 238. DOI: 10.1200/JCO.2022.40.4_suppl.238.
doi: 10.1200/JCO.2022.40.4_suppl.238 |
| [29] |
Li C, Zhao S, Zheng Y, et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)[J]. Eur J Cancer, 2021, 144: 232-241. DOI: 10.1016/j.ejca.2020.11.039.
doi: 10.1016/j.ejca.2020.11.039 pmid: 33373868 |
| [30] |
Sun H, Yang W, Luo J, et al. Safety and tolerability of neoadjuvant radiotherapy combined with anti-PD-1 antibody toripalimab for locally advanced, resectable esophageal squamous cell cancer: a prospective phase ⅠB trial[J]. Int J Radiat Oncol Biol Phys, 2021, 111(< W>3 Supplement): S102-S103. DOI: 10.1016/j.ijrobp.2021.07.238.
doi: 10.1016/j.ijrobp.2021.07.238 |
| [31] |
Liu J, Li Z, Fu X, et al. 127P A prospective phase Ⅱ clinical trial exploring neoadjuvant immunotherapy combined with chemotherapy in resectable thoracic esophageal squamous cell cancer (TESCC) with multi-station lymph node metastases (NICE study): preliminary results[J]. Ann Oncol, 2020, 31, Supplement 6: S1292. DOI: 10.1016/j.annonc.2020.10.148.
doi: 10.1016/j.annonc.2020.10.148 |
| [32] |
Liu S, Wen J, Yang H, et al. Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase Ⅲ trial NEOCRTEC5010[J]. Eur J Cancer, 2020, 138: 113-121. DOI: 10.1016/j.ejca.2020.08.002.
doi: 10.1016/j.ejca.2020.08.002 |
| [33] |
Lee Y, Samarasinghe Y, Lee MH, et al. Role of adjuvant therapy in esophageal cancer patients after neoadjuvant therapy and esophagectomy: a systematic review and meta-analysis[J]. Ann Surg, 2022, 275(1): 91-98. DOI: 10.1097/SLA.0000000000005227.
doi: 10.1097/SLA.0000000000005227 |
| [34] |
Burt BM, Groth SS, Sada YH, et al. Utility of adjuvant chemotherapy after neoadjuvant chemoradiation and esophagectomy for esophageal cancer[J]. Ann Surg, 2017, 266(2): 297-304. DOI: 10.1097/SLA.0000000000001954.
doi: 10.1097/SLA.0000000000001954 pmid: 27501170 |
| [35] |
Samson P, Puri V, Lockhart AC, et al. Adjuvant chemotherapy for patients with pathologic node-positive esophageal cancer after induction chemotherapy is associated with improved survival[J]. J Thorac Cardiovasc Surg, 2018, 156(4): 1725-1735. DOI: 10.1016/j.jtcvs.2018.05.100.
doi: S0022-5223(18)31547-2 pmid: 30054137 |
| [36] |
Huang PM, Hsu FM, Lin CC, et al. Do we need to add postoperative radiotherapy in patients undergoing trimodality therapy for esophageal squamous cell carcinoma with positive lymph nodes disease?[J]. Dig Surg, 2018, 35(2): 104-110. DOI: 10.1159/000477264.
doi: 10.1159/000477264 |
| [37] |
Hsu HY, Chao YK, Hsieh CH, et al. Postoperative adjuvant therapy improves survival in pathologic nonresponders after neoadjuvant chemoradiation for esophageal squamous cell carcinoma: a propensity-matched analysis[J]. Ann Thorac Surg, 2016, 102(5): 1687-1693. DOI: 10.1016/j.athoracsur.2016.05.026.
doi: 10.1016/j.athoracsur.2016.05.026 |
| [38] |
Semenkovich TR, Subramanian M, Yan Y, et al. Adjuvant therapy for node-positive esophageal cancer after induction and surgery: a multisite study[J]. Ann Thorac Surg, 2019, 108(3): 828-836. DOI: 10.1016/j.athoracsur.2019.04.099.
doi: S0003-4975(19)30864-1 pmid: 31229485 |
| [39] |
Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer[J]. N Engl J Med, 2021, 384(13): 1191-1203. DOI: 10.1056/NEJMoa2032125.
doi: 10.1056/NEJMoa2032125 |
| [40] |
Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): expanded efficacy and safety analyses from CheckMate 577[J]. J Clin Oncol, 2021, 39(< W>15 Suppl): 4003. DOI: 10.1200/JCO.2021.39.15_suppl.4003.
doi: 10.1200/JCO.2021.39.15_suppl.4003 |
| [41] |
Park S, Sun JM, Choi YL, et al. Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase Ⅱ study[J]. ESMO Open, 2022, 7(1): 100385. DOI: 10.1016/j.esmoop.2022.100385.
doi: 10.1016/j.esmoop.2022.100385 |
| [42] |
Lee S, Ahn BC, Park SY, et al. 1859P—a phase Ⅱ trial of pre-operative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC)[J]. Ann Oncol, 2019, 30, Supplement 5: v754. DOI: 10.1093/annonc/mdz266.018.
doi: 10.1093/annonc/mdz266.018 |
| [43] |
van den Ende T, de Clercq NC, van Berge Henegouwen MI, et al. Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: a single-arm phase Ⅱ feasibility trial (PERFECT)[J]. Clin Cancer Res, 2021, 27(12): 3351-3359. DOI: 10.1158/1078-0432.CCR-20-4443.
doi: 10.1158/1078-0432.CCR-20-4443 pmid: 33504550 |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||